Dallas, TX -- (SBWIRE) -- 03/10/2015 -- PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has a new presentation slot at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
PlasmaTech's President and CFO, Harrison Wehner, is now scheduled to present a corporate update on Wednesday, March 11, 2015 at 8:30 am Pacific Standard Time (Track 5: Salon 5), with one-on-one meeting availability throughout the conference. For more information about the conference or to schedule a one-one-one meeting with PlasmaTech management, please contact your ROTH representative at 1-800-933-6830 or via email at conference@roth.com.
A copy of the PlasmaTech presentation will be available on our corporate website at www.plasmatechbio.com.
About PlasmaTech Biopharmaceuticals, Inc.
PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The Company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, http://www.plasmatechbio.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue clinical trials and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission